Orasure Technologies Inc. (NASDAQ:OSUR) shares traded 0.97% higher at $7.25 on Wall Street last session.
In accordance with the data, 6 analysts cover Orasure Technologies Inc. (NASDAQ:OSUR). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $7.00 and a low of $5.00, we find $6.00. Given the previous closing price of $7.18, this indicates a potential downside of -16.43 percent. OSUR stock price is now 24.90% away from the 50-day moving average and 24.11% away from the 200-day moving average. The market capitalization of the company currently stands at $532.73M.
It has been rated a hold by 5 analysts and a buy by 1. Brokers who have rated the stock have averaged $6.00 as their price target over the next twelve months.
In other news, Anthony Michele Marie, SVP Finance & CAO sold 1,758 shares of the company’s stock on Aug 15. The stock was sold for $11,427 at an average price of $6.50. Upon completion of the transaction, the SVP Finance & CAO now directly owns 86,188 shares in the company, valued at $0.62 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 30, Chief Financial Officer McGrath Kenneth J bought 100,000 shares of the business’s stock. A total of $492,810 was incurred on buying the stock at an average price of $4.93. This leaves the insider owning 285,512 shares of the company worth $2.07 million. Insiders disposed of 130,603 shares of company stock worth roughly $0.95 million over the past 1 year. A total of 4.52% of the company’s stock is owned by insiders.
Orasure Technologies Inc. (NASDAQ: OSUR) opened at $7.23 on Wednesday. During the past 12 months, Orasure Technologies Inc. has had a low of $4.38 and a high of $7.82. As of last week, the company has a debt-to-equity ratio of 0.04, a current ratio of 8.71, and a quick ratio of 7.26. According to the stock market information, the enterprise value for the company is $322.89M, which is based on a 10.90 price-to-earnings ratio, a 0.55 price-to-earnings-growth ratio, and a beta of 0.20. The fifty day moving average price for OSUR is $5.80 and a two-hundred day moving average price translates $5.84 for the stock.
The latest earnings results from Orasure Technologies Inc. (NASDAQ: OSUR) was released for Sep, 2023. According to the Medical Instruments & Supplies Company, earnings per share came in at $0.15, beating analysts’ expectations of $0.04 by 0.11. This compares to $0.08 EPS in the same period last year. The net profit margin was 10.86% and return on equity was 13.16% for OSUR. The company reported revenue of $89.19 million for the quarter, compared to $116.46 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -23.42 percent. For the current quarter, analysts expect OSUR to generate $74.08M in revenue.
Orasure Technologies Inc.(OSUR) Company Profile
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company’s diagnostic products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgeneGUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
